Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, and there are currently no targeted agents approved for its treatment. It is increasingly being realized that this entity by itself is quite heterogenous and the use of biomarkers can help in better characterization of its prognosis and development of appropriate therapeutic strategies. Recently, androgen receptors (AR) and their signaling cascade have been increasingly evaluated in TNBC. Their exact role in the pathogenesis and progression of the disease is still obscured. Drugs like bicalutamide and enzalutamide have shown some activity in this subtype. This review will focus on the available evidence supporting the role of androgen receptors in the prognosis of TNBC and current status of therapies targeting these receptors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
